Ozanimod for treating moderately to severely active ulcerative colitis [ID3841] A Single Technology Appraisal
Brand, A; O'Toole, B; Muthukumar, M; et al.Matthews, J; Kiff, F; Shaw, N; Wilson, ECF; Digby-Bell, J; Crathorne, L; Melendez-Torres, GJ
Date: 5 October 2022
Report
Publisher
Peninsula Technology Assessment Group (PenTAG), University of Exeter
Abstract
Executive Summary: This summary provides a brief overview of the key issues identified by the evidence review group (ERG) as being potentially important for decision-making. It also includes the ERG’s preferred assumptions and the resulting incremental cost-effectiveness ratios (ICERs). • Section 1.1 provides an overview of the key ...
Executive Summary: This summary provides a brief overview of the key issues identified by the evidence review group (ERG) as being potentially important for decision-making. It also includes the ERG’s preferred assumptions and the resulting incremental cost-effectiveness ratios (ICERs). • Section 1.1 provides an overview of the key issues and the differences in the assumptions of the company and the ERG in economic analysis. • Section 1.2 provides an overview of key model outcomes and the modelling assumptions that have the greatest effect on the ICER. • Sections 1.3 to 1.5 explain the key issues in more detail. Background information on the condition, technology and evidence and information on non-key issues are in the main ERG report. • Sections 1.6 and 1.7 provide an overview of the ERG’s preferred base case and sensitivity analyses undertaken by the ERG. All issues identified represent the ERG’s view, not the opinion of the National Institute for Health and Care Excellence (NICE).
Public Health and Sport Sciences
Faculty of Health and Life Sciences
Item views 0
Full item downloads 0